• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    FDA Approval for NEOSTIGMINE METHYLSULFATE issued to AMPHASTAR PHARMS INC

    5/30/22 4:39:04 AM ET
    $AMPH
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $AMPH alert in real time by email
    Abbreviated New Drug Application (ANDA): 209933
    Company: AMPHASTAR PHARMS INC
    • Email

    Products on ANDA 209933

    Drug Name Active Ingredients Strength Dosage Form/Route Marketing Status TE Code RLD RS
    NEOSTIGMINE METHYLSULFATE NEOSTIGMINE METHYLSULFATE 5MG/10ML (0.5MG/ML) SOLUTION;INTRAVENOUS Prescription AP No No
    NEOSTIGMINE METHYLSULFATE NEOSTIGMINE METHYLSULFATE 10MG/10ML (1MG/ML) SOLUTION;INTRAVENOUS Prescription AP No No

    Approval Date(s) and History, Letters, Labels, Reviews for ANDA 209933

    Original Approvals or Tentative Approvals
    Action Date Submission Action Type Submission Classification Review Priority; Orphan Status Letters, Reviews, Labels, Patient Package Insert Notes Url
    09/25/2017 ORIG-1 Approval STANDARD

    Label is not available on this site.

    Supplements
    Action Date Submission Supplement Categories or Approval Type Letters, Reviews, Labels, Patient Package Insert Note Url
    05/19/2022 SUPPL-1 Labeling-Package Insert

    Label is not available on this site.

    Therapeutic Equivalents for ANDA 209933

    NEOSTIGMINE METHYLSULFATE

    SOLUTION;INTRAVENOUS; 5MG/10ML (0.5MG/ML)
    TE Code = AP

    Drug Name Active Ingredients Strength Dosage Form/Route Marketing Status RLD TE Code Application No. Company
    BLOXIVERZ NEOSTIGMINE METHYLSULFATE 5MG/10ML (0.5MG/ML) SOLUTION;INTRAVENOUS Prescription Yes AP 204078 EXELA PHARMA
    NEOSTIGMINE METHYLSULFATE NEOSTIGMINE METHYLSULFATE 5MG/10ML (0.5MG/ML) SOLUTION;INTRAVENOUS Prescription No AP 210051 AMNEAL
    NEOSTIGMINE METHYLSULFATE NEOSTIGMINE METHYLSULFATE 5MG/10ML (0.5MG/ML) SOLUTION;INTRAVENOUS Prescription No AP 209933 AMPHASTAR PHARMS INC
    NEOSTIGMINE METHYLSULFATE NEOSTIGMINE METHYLSULFATE 5MG/10ML (0.5MG/ML) SOLUTION;INTRAVENOUS Prescription No AP 210989 AMRING PHARMS
    NEOSTIGMINE METHYLSULFATE NEOSTIGMINE METHYLSULFATE 5MG/10ML (0.5MG/ML) SOLUTION;INTRAVENOUS Prescription No AP 212512 BE PHARMS
    NEOSTIGMINE METHYLSULFATE NEOSTIGMINE METHYLSULFATE 5MG/10ML (0.5MG/ML) SOLUTION;INTRAVENOUS Prescription No AP 213074 CAPLIN
    NEOSTIGMINE METHYLSULFATE NEOSTIGMINE METHYLSULFATE 5MG/10ML (0.5MG/ML) SOLUTION;INTRAVENOUS Prescription No AP 209135 DR REDDYS
    NEOSTIGMINE METHYLSULFATE NEOSTIGMINE METHYLSULFATE 5MG/10ML (0.5MG/ML) SOLUTION;INTRAVENOUS Prescription No AP 207042 EUROHLTH INTL SARL
    NEOSTIGMINE METHYLSULFATE NEOSTIGMINE METHYLSULFATE 5MG/10ML (0.5MG/ML) SOLUTION;INTRAVENOUS Prescription No AP 212968 GLAND PHARMA LTD
    NEOSTIGMINE METHYLSULFATE NEOSTIGMINE METHYLSULFATE 5MG/10ML (0.5MG/ML) SOLUTION;INTRAVENOUS Prescription No AP 210652 INDOCO
    NEOSTIGMINE METHYLSULFATE NEOSTIGMINE METHYLSULFATE 5MG/10ML (0.5MG/ML) SOLUTION;INTRAVENOUS Prescription No AP 212804 MEITHEAL
    NEOSTIGMINE METHYLSULFATE NEOSTIGMINE METHYLSULFATE 5MG/10ML (0.5MG/ML) SOLUTION;INTRAVENOUS Prescription No AP 208405 PAR STERILE PRODUCTS

    SOLUTION;INTRAVENOUS; 10MG/10ML (1MG/ML)
    TE Code = AP

    Drug Name Active Ingredients Strength Dosage Form/Route Marketing Status RLD TE Code Application No. Company
    BLOXIVERZ NEOSTIGMINE METHYLSULFATE 10MG/10ML (1MG/ML) SOLUTION;INTRAVENOUS Prescription Yes AP 204078 EXELA PHARMA
    NEOSTIGMINE METHYLSULFATE NEOSTIGMINE METHYLSULFATE 10MG/10ML (1MG/ML) SOLUTION;INTRAVENOUS Prescription No AP 210051 AMNEAL
    NEOSTIGMINE METHYLSULFATE NEOSTIGMINE METHYLSULFATE 10MG/10ML (1MG/ML) SOLUTION;INTRAVENOUS Prescription No AP 209933 AMPHASTAR PHARMS INC
    NEOSTIGMINE METHYLSULFATE NEOSTIGMINE METHYLSULFATE 10MG/10ML (1MG/ML) SOLUTION;INTRAVENOUS Prescription No AP 210989 AMRING PHARMS
    NEOSTIGMINE METHYLSULFATE NEOSTIGMINE METHYLSULFATE 10MG/10ML (1MG/ML) SOLUTION;INTRAVENOUS Prescription No AP 212512 BE PHARMS
    NEOSTIGMINE METHYLSULFATE NEOSTIGMINE METHYLSULFATE 10MG/10ML (1MG/ML) SOLUTION;INTRAVENOUS Prescription No AP 213074 CAPLIN
    NEOSTIGMINE METHYLSULFATE NEOSTIGMINE METHYLSULFATE 10MG/10ML (1MG/ML) SOLUTION;INTRAVENOUS Prescription No AP 209135 DR REDDYS
    NEOSTIGMINE METHYLSULFATE NEOSTIGMINE METHYLSULFATE 10MG/10ML (1MG/ML) SOLUTION;INTRAVENOUS Prescription No AP 207042 EUROHLTH INTL SARL
    NEOSTIGMINE METHYLSULFATE NEOSTIGMINE METHYLSULFATE 10MG/10ML (1MG/ML) SOLUTION;INTRAVENOUS Prescription No AP 212968 GLAND PHARMA LTD
    NEOSTIGMINE METHYLSULFATE NEOSTIGMINE METHYLSULFATE 10MG/10ML (1MG/ML) SOLUTION;INTRAVENOUS Prescription No AP 210652 INDOCO
    NEOSTIGMINE METHYLSULFATE NEOSTIGMINE METHYLSULFATE 10MG/10ML (1MG/ML) SOLUTION;INTRAVENOUS Prescription No AP 212804 MEITHEAL
    NEOSTIGMINE METHYLSULFATE NEOSTIGMINE METHYLSULFATE 10MG/10ML (1MG/ML) SOLUTION;INTRAVENOUS Prescription No AP 208405 PAR STERILE PRODUCTS
    Get the next $AMPH alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $AMPH

    DatePrice TargetRatingAnalyst
    5/12/2025$30.00Overweight → Neutral
    Analyst
    2/4/2025$66.00 → $36.00Overweight → Neutral
    Piper Sandler
    11/22/2024$55.00Equal Weight
    Wells Fargo
    3/5/2024$60.00Overweight
    JP Morgan
    11/17/2023$63.00Neutral
    BofA Securities
    7/25/2023$70.00Buy
    Jefferies
    10/21/2022$36.00Buy
    Jefferies
    7/29/2022$44.00Overweight
    CapitalOne
    More analyst ratings

    $AMPH
    SEC Filings

    See more
    • Amphastar Pharmaceuticals Inc. filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

      8-K - Amphastar Pharmaceuticals, Inc. (0001297184) (Filer)

      6/3/25 8:46:19 PM ET
      $AMPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-Q filed by Amphastar Pharmaceuticals Inc.

      10-Q - Amphastar Pharmaceuticals, Inc. (0001297184) (Filer)

      5/8/25 4:24:18 PM ET
      $AMPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amphastar Pharmaceuticals Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - Amphastar Pharmaceuticals, Inc. (0001297184) (Filer)

      5/7/25 4:23:10 PM ET
      $AMPH
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AMPH
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Amphastar Pharmaceuticals downgraded by Analyst with a new price target

      Analyst downgraded Amphastar Pharmaceuticals from Overweight to Neutral and set a new price target of $30.00

      5/12/25 8:19:14 AM ET
      $AMPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amphastar Pharmaceuticals downgraded by Piper Sandler with a new price target

      Piper Sandler downgraded Amphastar Pharmaceuticals from Overweight to Neutral and set a new price target of $36.00 from $66.00 previously

      2/4/25 6:58:07 AM ET
      $AMPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Wells Fargo initiated coverage on Amphastar Pharmaceuticals with a new price target

      Wells Fargo initiated coverage of Amphastar Pharmaceuticals with a rating of Equal Weight and set a new price target of $55.00

      11/22/24 7:19:52 AM ET
      $AMPH
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AMPH
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Amphastar Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference

      RANCHO CUCAMONGA, CA / ACCESSWIRE / January 8, 2025 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced today that Jack Zhang, CEO and President, and Bill Peters, CFO will be presenting at the 43rd Annual J.P. Morgan Healthcare Conference on Wednesday, January 15th, 2025, at 11:15 am PST. For access, visit Amphastar's Pharmaceuticals website at http://ir.amphastar.com. This webcast will be available for 30 days following the presentation.About Amphastar:Amphastar is a biopharmaceutical company that focuses primarily on developing, manufacturing, marketing, and selling technically-challenging generic and proprietary injectable, inhalation, and intranasal products. Additionally, the Comp

      1/8/25 6:00:00 AM ET
      $AMPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amphastar Pharmaceuticals to Present at the 36th Annual Piper Sandler Healthcare Conference

      RANCHO CUCAMONGA, CA / ACCESSWIRE / November 26, 2024 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced today that Bill Peters, CFO, and Dan Dischner SVP of Corp. Communication, will participate in an Analyst-Moderated fireside chat at the 36th Annual Piper Sandler Healthcare Conference on Wednesday, December 4th, 2024 at 11:30 am EST. For access, visit Amphastar's Pharmaceuticals website at http://ir.amphastar.com. This webcast will be available for 30 days following the presentation.About Amphastar:Amphastar is a biopharmaceutical company that focuses primarily on developing, manufacturing, marketing, and selling technically-challenging generic and proprietary injectable, inhalatio

      11/26/24 4:05:00 PM ET
      $AMPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amphastar Pharmaceuticals to Present at the Jefferies London Healthcare Conference

      RANCHO CUCAMONGA, CA / ACCESSWIRE / November 13, 2024 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced today that Bill Peters, CFO, and Jacob Liawatidewi, EVP of Corporate Administration, will participate in an Analyst-Moderated fireside chat at the Jefferies London Healthcare Conference on Wednesday, November 20, 2024 at 3:30 pm GMT. For access, visit Amphastar's Pharmaceuticals website at http://ir.amphastar.com. This webcast will be available for 30 days following the presentation.About Amphastar:Amphastar is a biopharmaceutical company that focuses primarily on developing, manufacturing, marketing, and selling technically-challenging generic and proprietary injectable, inhalatio

      11/13/24 4:05:00 PM ET
      $AMPH
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AMPH
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Petersen Floyd F. sold $11,734 worth of shares (500 units at $23.47), decreasing direct ownership by 0.64% to 77,531 units (SEC Form 4)

      4 - Amphastar Pharmaceuticals, Inc. (0001297184) (Issuer)

      7/3/25 5:30:47 PM ET
      $AMPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CEO & CHIEF SCIENTIFIC OFFICER Zhang Jack Y. exercised 200,000 shares at a strike of $13.03, increasing direct ownership by 8% to 2,847,659 units (SEC Form 4)

      4 - Amphastar Pharmaceuticals, Inc. (0001297184) (Issuer)

      6/16/25 5:19:35 PM ET
      $AMPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Lee Howard was granted 5,122 shares and covered exercise/tax liability with 923 shares, increasing direct ownership by 3% to 151,976 units (SEC Form 4)

      4 - Amphastar Pharmaceuticals, Inc. (0001297184) (Issuer)

      6/4/25 8:04:41 PM ET
      $AMPH
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AMPH
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more
    • FDA Approval for MEDROXYPROGESTERONE ACETATE issued to AMPHASTAR PHARMS INC

      Submission status for AMPHASTAR PHARMS INC's drug MEDROXYPROGESTERONE ACETATE (SUPPL-5) with active ingredient MEDROXYPROGESTERONE ACETATE has changed to 'Approval' on 01/25/2024. Application Category: ANDA, Application Number: 077334, Application Classification: Labeling

      1/26/24 4:40:02 AM ET
      $AMPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • FDA Approval for CORTROSYN issued to AMPHASTAR PHARMS INC

      Submission status for AMPHASTAR PHARMS INC's drug CORTROSYN (SUPPL-33) with active ingredient COSYNTROPIN has changed to 'Approval' on 12/22/2023. Application Category: NDA, Application Number: 016750, Application Classification: Labeling

      12/27/23 4:38:39 AM ET
      $AMPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • FDA Approval for NALOXONE HYDROCHLORIDE issued to AMPHASTAR PHARMS INC

      Submission status for AMPHASTAR PHARMS INC's drug NALOXONE HYDROCHLORIDE (SUPPL-1) with active ingredient NALOXONE HYDROCHLORIDE has changed to 'Approval' on 06/29/2023. Application Category: NDA, Application Number: 208969, Application Classification: Labeling

      6/30/23 9:33:25 AM ET
      $AMPH
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AMPH
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Amphastar Pharmaceuticals Inc. (Amendment)

      SC 13G/A - Amphastar Pharmaceuticals, Inc. (0001297184) (Subject)

      3/6/24 10:23:26 AM ET
      $AMPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Amphastar Pharmaceuticals Inc. (Amendment)

      SC 13G/A - Amphastar Pharmaceuticals, Inc. (0001297184) (Subject)

      2/13/24 4:58:53 PM ET
      $AMPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Amphastar Pharmaceuticals Inc. (Amendment)

      SC 13G/A - Amphastar Pharmaceuticals, Inc. (0001297184) (Subject)

      2/9/24 5:21:50 PM ET
      $AMPH
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AMPH
    Financials

    Live finance-specific insights

    See more
    • Amphastar Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference

      RANCHO CUCAMONGA, CA / ACCESSWIRE / January 8, 2025 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced today that Jack Zhang, CEO and President, and Bill Peters, CFO will be presenting at the 43rd Annual J.P. Morgan Healthcare Conference on Wednesday, January 15th, 2025, at 11:15 am PST. For access, visit Amphastar's Pharmaceuticals website at http://ir.amphastar.com. This webcast will be available for 30 days following the presentation.About Amphastar:Amphastar is a biopharmaceutical company that focuses primarily on developing, manufacturing, marketing, and selling technically-challenging generic and proprietary injectable, inhalation, and intranasal products. Additionally, the Comp

      1/8/25 6:00:00 AM ET
      $AMPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amphastar Pharmaceuticals to Present at the 36th Annual Piper Sandler Healthcare Conference

      RANCHO CUCAMONGA, CA / ACCESSWIRE / November 26, 2024 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced today that Bill Peters, CFO, and Dan Dischner SVP of Corp. Communication, will participate in an Analyst-Moderated fireside chat at the 36th Annual Piper Sandler Healthcare Conference on Wednesday, December 4th, 2024 at 11:30 am EST. For access, visit Amphastar's Pharmaceuticals website at http://ir.amphastar.com. This webcast will be available for 30 days following the presentation.About Amphastar:Amphastar is a biopharmaceutical company that focuses primarily on developing, manufacturing, marketing, and selling technically-challenging generic and proprietary injectable, inhalatio

      11/26/24 4:05:00 PM ET
      $AMPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amphastar Pharmaceuticals to Present at the Jefferies London Healthcare Conference

      RANCHO CUCAMONGA, CA / ACCESSWIRE / November 13, 2024 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced today that Bill Peters, CFO, and Jacob Liawatidewi, EVP of Corporate Administration, will participate in an Analyst-Moderated fireside chat at the Jefferies London Healthcare Conference on Wednesday, November 20, 2024 at 3:30 pm GMT. For access, visit Amphastar's Pharmaceuticals website at http://ir.amphastar.com. This webcast will be available for 30 days following the presentation.About Amphastar:Amphastar is a biopharmaceutical company that focuses primarily on developing, manufacturing, marketing, and selling technically-challenging generic and proprietary injectable, inhalatio

      11/13/24 4:05:00 PM ET
      $AMPH
      Biotechnology: Pharmaceutical Preparations
      Health Care